Unravelling the complex dissociation of [3H]-rimonabant from plated CB1 cannabinoid receptor-expressing cells

Fundamental and Clinical Pharmacology

Volumn 24, Issue 2, 2010, Pages 181-187

  Wennerberg, M ^a   Balendran, A ^a   Clapham, J C ^b   Vauquelin, Georges ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

CB1 cannabinoid receptor; Dissociation kinetics; Membrane partitioning; Radioligand binding; Rebinding; Rimonabant

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BOVINE SERUM ALBUMIN; CANNABINOID 1 RECEPTOR; RIMONABANT;

ARTICLE; CELL LEVEL; CELL MEMBRANE; CELL STRAIN HEK293; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DISSOCIATION; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HYDROPHOBICITY; PRIORITY JOURNAL; TEMPERATURE;

ANIMALS; CATTLE; CELL LINE; CELL MEMBRANE; HUMANS; PIPERIDINES; PROTEIN BINDING; PYRAZOLES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB1; SERUM ALBUMIN, BOVINE;

EID: 77949887689     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00756.x     Document Type: Article

References (38)

1. Copeland R.A., Pompliano D.L., Meek T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. (2006) 5 730 739.
2. Vauquelin G., Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol. Sci. (2006) 27 356 359.
3. Tummino P.J., Copeland R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry (2008) 47 5487 5492.
4. Vauquelin G., Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Neurochem. Int. (2007) 51 254 260.
5. Fierens F., Vanderheyden P.M., De Backer J.P., Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur. J. Pharmacol. (1999) 367 413 422.
6. Packeu A., De Backer J.P., Van Liefde I., Vanderheyden P.M., Vauquelin G. Antagonist-radioligand binding to D2L-receptors in intact cells. Biochem. Pharmacol. (2008) 75 2192 2203.
7. Howlett A.C., Barth F., Bonner T.I. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54 161 202.
8. Mackie K. Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. (2008) 20 10 14.
9. Herkenham M., Lynn A.B., Little M.D., et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA (1990) 87 1932 1936.
10. Armstrong H.E., Galka A., Lin L.S., et al. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists. Bioorg. Med. Chem. Lett. (2007) 17 2184 2187.
11. Addy C., Rothenberg P., Li S, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J. Clin. Pharmacol. (2008) 48 734 744.
12. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365 1389 1397.
13. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295 761 775.
14. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353 2121 2134.
15. Turu G., Simon A., Gyombolai P., et al. The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity. J. Biol. Chem. (2007) 282 7753 7757.
16. Rinaldi-Carmona M., Pialot F., Congy C., et al. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. (1996) 58 1239 1247.
17. Rinaldi-Carmona M., Barth F., Heaulme M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350 240 244.
18. Jung M., Calassi R., Rinaldi-Carmona M., et al. Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. J. Neurochem. (1997) 68 402 409.
19. Hara M., Tozawa F., Itazaki K., Mihara S., Fujimoto M. Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations. Eur. J. Pharmacol. (1998) 345 339 342.
20. Fierens F.L., Vanderheyden P.M., Roggeman C., Vande Gucht P., De Backer J.P., Vauquelin G. Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations. Biochem. Pharmacol. (2002) 63 1273 1279.
21. Smith C., Rahman R., Toohey N., Marukiewicz J., Herrick-Davis K., Teitler M. Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol. Pharmacol. (2006) 70 1264 1270.
22. Goldstein B., Posner R.G., Torney D.C., Erickson J., Holowka D., Baird B. Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys. J. (1989) 56 955 966.
23. Muccioli G.G., Lambert D.M. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem. (2005) 12 1361 1394.
24. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. (1997) 61 PL 191 PL 197.
25. Lan R., Liu Q., Fan P., et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. (1999) 42 769 776.
26. Sargent D.F., Bean J.W., Schwyzer R. Conformation and orientation of regulatory peptides on lipid membranes. Key to the molecular mechanism of receptor selection. Biophys. Chem. (1988) 31 183 193.
27. Herbette L.G., Trumbore M., Chester D.W., Katz A.M. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone. J. Mol. Cell. Cardiol. (1988) 20 373 378.
28. Le M.T., Pugsley M.K., Vauquelin G., Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br. J. Pharmacol. (2007) 151 952 962.
29. Spivak C.E., Oz M., Beglan C.L., Shrager R.I. Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells: radioligand binding, confocal microscopy, and mathematical simulations. Cell Biochem. Biophys. (2006) 45 43 58.
30. Chu C.L., Buczek-Thomas J.A., Nugent M.A. Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. Biochem. J. (2004) 379 331 341.
31. Simard J.R., Zunszain P.A., Hamilton J.A., Curry S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol. (2006) 361 336 351.
32. Gopalakrishnan M., Forsten-Williams K., Nugent M.A., Tauber U.C. Effects of receptor clustering on ligand dissociation kinetics: theory and simulations. Biophys. J. (2005) 89 3686 3700.
33. Johnson M., Butchers P.R., Coleman R.A., et al. The pharmacology of salmeterol. Life Sci. (1993) 52 2131 2143.
34. Anderson G.P., Linden A., Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting? Eur. Respir. J. (1994) 7 569 578.
35. Coleman R.A., Johnson M., Nials A.T., Vardey C.J. Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends Pharmacol. Sci. (1996) 17 324 330.
36. Makriyannis A., Tian X., Guo J. How lipophilic cannabinergic ligands reach their receptor sites. Prostaglandins Other Lipid Mediat. (2005) 77 210 218.
37. Tian X., Guo J., Yao F., Yang D.P., Makriyannis A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J. Biol. Chem. (2005) 280 29788 29795.
38. Coombs D., Goldstein B. Effects of the geometry of the immunological synapse on the delivery of effector molecules. Biophys. J. (2004) 87 2215 2220.